Data from a trial revealed that after a 24 month observation period there was improved bone growth in the patients treated with GEM 21S.
GEM 21S works by combining a principal wound healing stimulator in the body with Beta-TCP, a synthetic bone matrix often used to treat bone injuries. X-rays of bone growth showed that there was a statistically significant increase when using GEM 21S compared to Beta TCP alone. Further, bone formation in the Beta-TCP matrix alone group never achieved the degree of bone formation during the 24 month period as was observed at 6 months in the GEM 21S group.
“I am impressed with the long-term success of GEM 21S to stimulate new bone growth,” said Dr William Giannobile, Director of the Michigan Center for Oral Health Research, University of Michigan. “These results continue to support the long-term effectiveness of the product and further demonstrate the value of GEM 21S as a therapeutic to stimulate bone regeneration at sites of advanced periodontal disease.”